Small molecule · Antagonist of muscarinic acetylcholine receptor · developed by Janssen Pharms
R-oxybutynin is the R-isomer of oxybutynin, the isomer that carries most of the antimuscarinic activity of the racemic mixture. It acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, relaxing bladder smooth muscle. It is being studied in obstructive sleep apnea, given orally before bed.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 29, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04580394 | Phase 2 | Obstructive Sleep Apnea | Completed | APMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Obstructive Sleep Apnea
Updated Oct 11, 2026.